Channels
BioPortfolio's Channels offers visitors a single point of access to life science and healthcare subjects, technologies, products and services. For example ImmTAC developed by Immunocore, PolyXen developed by Xenetic Biosciences. Each dedicated Channel web page provides highly specific information sourced from BioPortfolio's unique collection of databases - news stories, corporate directory, clinical trials, medical and scientific information.
Organizations can request specific channel pages to be created to promote their products, technologies, research tools and services. BioPortfolio makes a nominal charge of between $40 to $50 per web page published. Each bespoke Channel page is managed by the registered member who can edit and amend over the 12 month subscription period. To start publishing content on BioPortfolio's Channels open http://www.bioportfolio.net/report/23346-biochannel-publish-content-on-products-technologies.html
Interested? Contact priority@bioportfolio.com
Showing Channels 1–25 of 4,400+
Antisense therapy is a form of treatment for genetic disorders or infections. When the genetic sequence of a particular gene is known to be causative of a particular disease, it is possible to synthesize a strand of nucleic acid that will bind to the mes...
Lupus : A major unmet medical need Lupus is a chronic and severe autoimmune disease in which the immune system produces antibodies to cells within the body leading to widespread inflammation and tissue damage. It may affect multiple organ systems, incl...
Therapies targeting TNF have already demonstrated efficacy across a wide range of inflammatory diseases, including rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondulitis, psoriasis and Crohn’s disease. The target market for Kin...
A glycoengineered, fully humanized IgG1 monoclonal antibody with potential antineoplastic activity. Obinutuzumab, a third generation type II anti-CD20 antibody, selectivity binds to the extracellular domain of the human CD20 antigen on malignant human B...
UroGenRA - Genitourinary cancer array
UroGenRA is a CGI custom-designed oligonucleotide array for implementation within a clinical laboratory as an array CGH-based diagnostic/prognostic tool for kidney, prostate, and bladder cancers. It was designed to detect gains and losses that frequently...
UGenRA - Genitourinary cancer array
UGenRA is a CGI custom-designed oligonucleotide array designed to detect gains and losses of genomic material in endometrial, ovarian, and cervical cancers. Endometrial hyperplasia is a precursor lesion of endometriod endometrial carcinoma (EEC) and sinc...
MatBA - Mature B-cell neoplasm array
Mature B-cell neoplasms arise in B-cells that have entered germinal centers within lymph nodes as part of the immune response. They display great heterogeneity at the clinical, pathologic, and genetic levels and represent 6-7% and 5-6% of all new estimat...
Fluorescent in situ hybridization (FISH) is a sensitive and accurate technique that allows the detection of chromosome aberrations. In this method, a single-stranded fluorescent-labeled nucleic acid sequence (probe) complementary to a target genomic sequ...
Coronavirus were first identified in the 1960s, and were named after the crown-like projections on the surface of the virus. They cause respiratory infections in both humans and animals. Coronaviruses are a large family of viruses that includes viruses...
Avian influenza A H7 viruses are a group of influenza viruses that normally circulate among birds. The avian influenza A(H7N9) virus is one subgroup among the larger group of H7 viruses. Although some H7 viruses (H7N2, H7N3 and H7N7) have occasionally be...
For optimal treatment in cancerology, clinicians need specific, precise, sensitive methods to quantify treatment response, monitor residual disease and detect early recurrence in patients. Residual disease monitoring has become common practice in many ha...
At OncoDNA, our philosophy is to provide the most suitable test in terms of rapidity and cost. That’s why we follow a 3 tier approach to find tumour mutations which can respond to new cancer therapies,. We always do the test OncoDEEP DX version fi...
Eliglustat acts at a level above the defective enzyme in Gaucher disease and reduces the amount of a toxic metabolite (glucosylceramide) that is the target of enzyme replacement therapy.
Lemtrada (alemtuzumab) is being developed by Sanofi in collaboration with Bayer Healthcare for the treatment of relapsing multiple sclerosis.
KYNAMRO (mipomersen sodium) injection is an oligonucleotide inhibitor of apolipoprotein B-100 synthesis indicated as an adjunct to lipid-lowering medications and diet to reduce low density lipoprotein-cholesterol (LDL-C), apolipoprotein B (apo B), total...
Lyxumia® is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) for the treatment of patients with type 2 diabetes mellitus. GLP-1 is a naturally-occurring peptide hormone that is released within minutes after eating a meal. It is kn...
ZALTRAP®, in combination with 5-fluorouracil, leucovorin, irinotecan-(FOLFIRI), is indicated for patients with metastatic colorectal cancer (mCRC) that is resistant to or has progressed following an oxaliplatin-containing regimen.
Kadcyla (ado-trastuzumab emtansine)
Kadcyla™ (ado-trastuzumab emtansine or T-DM1) for the treatment of people with HER2-positive metastatic breast cancer (mBC) who have received prior treatment with Herceptin® (trastuzumab) and a taxane chemotherapy. Kadcyla is the fourth medicin...
Aorfix™ endovascular stent graft – Treating the cases other grafts cannot treat Aorfix™ is the only endovascular stent graft licensed in Europe to treat aneurysms in complex anatomies with neck angulations of up to 90°. The Aor...
CombiCult® is an award winning, combinatorial screening technology that allows scientists to discover new and improved stem cell differentiation protocols. How Combicult® works A short overview on how Plasticell uses combinatorial cell cultur...
Oncohist™ exhibits the same properties as the body's own histone H1.3 molecules and has consequently low immunogenicity and antigenicity. Extensive data have shown that Oncohist molecules have the ability to destabilize selectively the tumor ce...
ImuXen® is a liposomal technology platform designed to improve the delivery and effectiveness of DNA, protein and polysaccharide vaccines. Proof of concept preclinical studies with a number of vaccines have shown that ImuXen® technology can hel...
PolyXen® is an enabling technology for protein drug delivery. It uses the natural polymer polysialic acid (PSA) to prolong the active life and improve the stability of therapeutic peptides and proteins. It can also be used for small molec...
Immunocore’s ImmTAC technology enables the immune system to recognise and kill cancer or viral cells. T Cell Receptors naturally recognise diseased cells and Immunocore’s competitive advantage is its ability to engineer high affinity T Cell...
Gaucher's (go-SHAYZ) disease occurs when certain harmful fatty substances accumulate to excessive levels in your liver, spleen, lungs, bone marrow and, less commonly, brain. This accumulation of fatty material in tissues interferes with how your body...
